MENU
CRVS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Corvus Pharmaceuticals (CRVS) Earnings Date & Reports

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function... Show more

A.I. Advisor
published Earnings

CRVS is expected to report earnings to fall 10.23% to -19 cents per share on March 24

Corvus Pharmaceuticals CRVS Stock Earnings Reports
Q4'26
Est.
$-0.20
Q3'26
Missed
by $0.01
Q2'26
Missed
by $0.04
Q1'26
Est.
$-0.15
Q4'25
Missed
by $0.02
The last earnings report on November 05 showed earnings per share of -21 cents, missing the estimate of -20 cents. With 112.07K shares outstanding, the current market capitalization sits at 886.63M.
A.I.Advisor
Nov 05, 2026

Corvus Pharmaceuticals (CRVS) Q3 2026 Earnings Recap: Spending Climbs as the Pipeline Advances

Key Takeaways

  • Corvus Pharmaceuticals (CRVS) reported a third-quarter 2026 net loss of $20.3 million, or $0.22 per diluted share, versus a $10.2 million loss in the year-ago quarter.
  • Research and development (R&D) expense rose roughly 110% to about $17.8 million as clinical programs for lead candidate soquelitinib expanded.
  • The company closed the quarter with approximately $200 million in cash, cash equivalents, and marketable securities, supporting a projected runway into the second quarter of 2028.
  • Enrollment in the registrational Phase 3 trial for relapsed/refractory peripheral T-cell lymphoma (PTCL) and the Phase 2 atopic dermatitis trial remains on track.
  • Partner Angel Pharmaceuticals completed Cohort 1 enrollment in its atopic dermatitis trial, with topline data anticipated in March 2027.
  • For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages on Tickeron.
  • Discover Trending AI Robots to see AI-driven trading strategies currently drawing attention in the market.

Earnings Context and Why It Matters

Corvus Pharmaceuticals is a clinical-stage biotechnology company with no product revenue, so its quarterly results are less about sales growth and more about the pace of clinical investment and the strength of its balance sheet. The company is pioneering ITK (interleukin-2-inducible T cell kinase) inhibition as a new immunotherapy approach, with lead candidate soquelitinib in a registrational Phase 3 PTCL study and mid-stage trials in atopic dermatitis and hidradenitis suppurativa. Because losses widen as these programs scale up, investors track both the burn rate and clinical execution. This report matters because it signals how efficiently Corvus is advancing toward pivotal data readouts while preserving the cash needed to reach them.

Reported Results

For the third quarter ended September 30, 2026, Corvus reported a net loss of $20.3 million, compared with $10.2 million in the same period of 2025. The diluted net loss per share was $0.22, versus $0.12 a year earlier and slightly wider than the consensus estimate of a $0.21 per-share loss.

The wider loss was driven primarily by higher R&D spending, which climbed about 110% to roughly $17.8 million, reflecting increased clinical trial costs for soquelitinib and higher personnel-related expenses. General and administrative (G&A) costs also rose to approximately $3.6 million. These were partially offset by higher interest and other income of about $1.9 million. The company recorded a non-cash equity-method loss of roughly $0.9 million tied to its 49% stake in Angel Pharmaceuticals, and stock-based compensation expense increased to about $2.8 million.

Corvus generated no revenue during the period. As of September 30, 2026, the company reported approximately $200 million in cash, cash equivalents, and marketable securities, which management expects to fund operations into the second quarter of 2028.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotechnology names like Corvus Pharmaceuticals, it offers a structured way to monitor momentum, volatility, and setup quality across the sector.

Market Reaction and Investor Sentiment

Because Corvus does not yet generate revenue, Wall Street tends to weigh clinical milestones and cash runway more heavily than the bottom-line loss itself. Heading into the print, sentiment was focused on whether the company could sustain its expanded Phase 3 PTCL and Phase 2 atopic dermatitis programs without pressuring its strengthened balance sheet. The modestly wider-than-expected loss was consistent with the company's communicated acceleration of soquelitinib development. Key risk factors for sentiment include the inherently binary nature of clinical trial outcomes, the rising pace of spending, and competition in immunology and oncology. Investors remain most sensitive to enrollment timelines and upcoming data readouts rather than the quarterly EPS (earnings per share) figure.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central story for Corvus is the advancement of soquelitinib across multiple indications. The registrational Phase 3 trial in relapsed/refractory PTCL is the company's nearest path to a potential regulatory filing, and investors will watch enrollment progress and any updates on trial timelines closely.

In atopic dermatitis, two important readouts are approaching. Angel Pharmaceuticals has completed enrollment in Cohort 1 of its Phase 1b/2 trial in China, with topline data expected in March 2027. Angel is also moving to enroll Cohort 2 beginning in November 2026, with data from that cohort potentially available in the second half of 2027.

Additional catalysts include the Phase 1b hidradenitis suppurativa trial initiated in September 2026 and continued execution across the broader clinical pipeline. On the financial side, the key metric to monitor is the R&D burn rate, which is likely to remain elevated as trials expand, against the roughly $200 million cash position that management projects will fund operations into the second quarter of 2028. As a clinical-stage company, Corvus remains exposed to trial, regulatory, and competitive risks that could materially shift its outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of anticancer immuno-oncology drugs

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
901 Gateway Boulevard, Third Floor
Phone
+1 650 900-4520
Employees
37
Web
https://www.corvuspharma.com